Transcatheter aortic valve replacement (TAVR) procedures with a self-expanding artificial valve are “very viable and safe” for low-risk patients with a bicuspid aortic valve, according to new research that tracked the outcomes of 150 patients.
Of COVID-19 patients who develop serious heart complications, most don’t see this problem until late in the disease’s progression. However, some are turning up with extensive heart inflammation at the outset.
The largest comprehensive study of congenital heart disease to date has revealed that, despite an overall decline in mortality over the past few decades, a child’s odds of surviving a CHD diagnosis hinge on the economic health of their community.
An analysis of PARTNER 2 data published in the New England Journal of Medicine Jan. 29 suggests five-year post-op outcomes are similar among heart patients who undergo either transcatheter or surgical aortic valve replacement.
Injection drug users prescribed controlled release hydromorphone—an opioid—are three times more likely to develop endocarditis than users prescribed other opioids, according to work published Jan. 22 in TheLancet Infectious Diseases.